



FINANCIAL TEAR SHEET

Corporate Profile

Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and pain management, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its two Pernix sales forces and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.

Primary IR Contact

Matthew Duffy
LifeSci Advisors
Phone: 212-915-0685
E-mail:
Matthew@lifesciadvisors.com

Stock Information

PTX.O (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$4.45
Change (%)	0.00 (0.00%)
Volume	0
52 Week Low	\$1.83
Market Cap	\$44,569,602
Rolling EPS	-19.51
PE Ratio	0
Shares Outstanding	10,015,641

Data as of 06/22/17 4:00 p.m. ET



Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent Press Releases & Upcoming Events

May 15, 2017 - 4:01 p.m.

Pernix Therapeutics Reports First Quarter 2017
Financial Results and Provides Business Update

May 8, 2017 - 4:01 p.m.

Pernix Therapeutics to Report First Quarter 2017
Financial Results on Monday, May 15

May 1, 2017 - 8:00 a.m.

Pernix Therapeutics Provides Update on
Availability of Zohydro® ER with BeadTek™ 20mg
Strength

There are currently no events scheduled.

SEC Filings

Filing Date	Form
05/15/17	10-Q
05/15/17	8-K
05/01/17	10-K/A
04/20/17	8-K

Corporate Governance

John Sedor	Chairman of the Board and CEO
Graham Miao	President and CFO
Kenneth R. Piña	Senior Vice President, General Counsel and Chief Compliance Officer
Cindy Lehrer	Vice President, Human Resources
George P. Jones	Vice President of Sales and Marketing
Angus Smith	Vice President, Business Development & Strategic Planning